Audio Insights

Jane Hermansen, Network Manager at Mayo Medical Laboratories, talks about the upcoming Leveraging the Laboratory conference in Philadelphia, Pennsylvania.

Sue Cloutier, Operations Manager, and Julie Bicknese, Supervisor, at Mayo Clinic, talk about their upcoming breakout session on leveraging customer service at Leveraging the Laboratory 2017 in Philadelphia, Pennsylvania.

Sharon Zehe, Legal Counsel at Mayo Clinic, talks about her upcoming breakout session on legal updates at Leveraging the Laboratory 2017 in Philadelphia, Pennsylvania.

Mike Baisch, Principal Systems Engineer at Mayo Clinic, talks about his upcoming breakout session on staffing to workload at Leveraging the Laboratory 2017 in Philadelphia, Pennsylvania.

Audio Insights: Chat with the Chair—Leadership Vol. 2 by Mayo Medical Laboratories

Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic, provides an overview of the lysosomal storage disorders screen.

Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic, discusses the drawbacks of the Lysosomal Storage Disorders Screen.

Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic discusses how this test improves upon previous approaches to Lysosomal Storage Disorder screening.

Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic, discusses what clinical actions the results allow you to take.

Gessi Bentz Pino, CGS, a Genetic Counselor in the Department of Laboratory Medicine and Pathology at Mayo Clinic, discusses when it is appropriate to order this test.

Mayo Medical Laboratories President William Morice, M.D., Ph.D., sits down with the new chair of the Mayo Clinic Division of Anatomic Pathology, Amy Clayton, M.D. The two discuss the role, leadership, and a shared history.

On Tuesday, we had a quick conversation with Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. We discussed their presentations and sessions.

One of our busiest laboratory directors, Melissa Snyder, Ph.D., spent a couple spare minutes with us to discuss her presentations and what she looks forward to most at AACC.

After her morning symposium yesterday, we ran into Linnea Baudhuin, Ph.D., who presented, "Bigger Always Better? Pros and Cons of Targeted vs Comprehensive Genetic Testing." Her co-presenter was Carol Saunders, Ph.D. She ended our conversation by previewing Tuesday's, "Laboratory Medicine Family Feud: AACC Leadership vs SYCL" symposium.

We caught up with Maria Alice Willrich, Ph.D., who presented a mid-day short course on Monday, July 31. The course was titled, "The Complement System: Overview and Laboratory Testing" and she co-presented with a colleague from the University of Colorado, Ashley Frazer-Abel, Ph.D.

Pat Hlavka, CSP, Safety Coordinator, and Deb Hagen-Moe, Education Coordinator, discuss a variety of safety education resources and training at Mayo Clinic.

Nicole Hoppman, Ph.D. discusses advantages of the Cell-Free DNA Prenatal Screen. This test detects common chromosome abnormalities without the risk of pregnancy loss associated with invasive prenatal procedures. Chromosomal aneuploidy is the leading known genetic cause of miscarriage and congenital birth defects, including Down syndrome, trisomy 13, and trisomy 18. This fetal DNA screening test is not diagnostic. Abnormal results should be confirmed with invasive prenatal diagnostic testing (such as chorionic villi sampling or amniocentesis). Genetic consultation is recommended.

Nicole Hoppman, Ph.D. discusses clinical application of Cell-Free DNA Prenatal Screen. This test detects common chromosome abnormalities without the risk of pregnancy loss associated with invasive prenatal procedures. Chromosomal aneuploidy is the leading known genetic cause of miscarriage and congenital birth defects, including Down syndrome, trisomy 13, and trisomy 18. This fetal DNA screening test is not diagnostic. Abnormal results should be confirmed with invasive prenatal diagnostic testing (such as chorionic villi sampling or amniocentesis). Genetic consultation is recommended.

Nicole Hoppman, Ph.D. discusses ordering scenarios of the Cell-Free DNA Prenatal Screen. This test detects common chromosome abnormalities without the risk of pregnancy loss associated with invasive prenatal procedures. Chromosomal aneuploidy is the leading known genetic cause of miscarriage and congenital birth defects, including Down syndrome, trisomy 13, and trisomy 18. This fetal DNA screening test is not diagnostic. Abnormal results should be confirmed with invasive prenatal diagnostic testing (such as chorionic villi sampling or amniocentesis). Genetic consultation is recommended.

Nicole Hoppman, Ph.D. provides an overview of the Cell-Free DNA Prenatal Screen. This test detects common chromosome abnormalities without the risk of pregnancy loss associated with invasive prenatal procedures. Chromosomal aneuploidy is the leading known genetic cause of miscarriage and congenital birth defects, including Down syndrome, trisomy 13, and trisomy 18. This fetal DNA screening test is not diagnostic. Abnormal results should be confirmed with invasive prenatal diagnostic testing (such as chorionic villi sampling or amniocentesis). Genetic consultation is recommended.